Adam M. Brufsky, MD, PhD, FACP; Francisco Esteva, MD, PhD; Hope S. Rugo, MD; Lee Schwartzberg, MD, FACP; and Komal Jhaveri, MD, FACP, discuss the optimal chemotherapy backbone for neoadjuvant therapy in women with HER2-positive breast cancer based on data from the 2017 SABCS meeting.